Congratulations to Richard Macaulay on his well-attended presentation “The New SMC-Ultra-Orphan Pathway: HTA Best Practice for Very Rare Diseases?” at Virtual ISPOR 2021. Did you miss Richard’s presentation?
Clare Sarvary Fourrier, SVP of Operational Strategy (EU) for Precision for Medicine moderates this panel discussion with industry experts to share perspectives on the current state of the cell and gene therapy industry and provide key insights in shortening time-to-market for advanced therapies.
Attending Virtual ISPOR 2021 May 17-20? PRECISIONadvisors and PRECISIONheor will be attending with multiple posters, presentations, and workshops. Three posters and one presentation will have a special focus on Orphan diseases. Stay tuned for valuable insights from our experts that you won’t want to miss!
Did you miss PRECISIONadvisor’s Richard Macaulay present “The Future of Reimbursement for Cell & Gene Therapies” at World EPA Congress 2021? Don’t miss great insights about cell & gene therapy reimbursement challenges.
Directly following the cell therapy panel discussion in part 1, Precision experts Phil Cyr, Deb Phippard and David Parker, and Project Pharma’s Tony Khoury joined C-Suite leaders from advanced therapy companies for “Considerations for the Clinical Development of Cell & Gene Therapies.” Part 2- Gene Therapy.
Miss ASGCT 2021? Check out this cell therapy panel discussion you won’t want to miss! Precision experts David Parker, Alex Grosvenor and Megan Liles, and Project Farma’s John Khoury join biotech executives on the front lines of development for “Considerations for the Clinical Development of Cell & Gene Therapies.” Part 1 – Cell Therapy.
The growing skills gaps in cell and gene therapy have resulted in a bottleneck preventing potentially revolutionary treatments from reaching the patients who need them. Phil Massey and Daniel Foody of Project Farma, part of the Precision ADVANCE collective, weigh in on the effects of the talent gap, and discuss strategies for closing the gap.
Congratulations to PRECISIONadvisor’s Richard Macaulay on presenting “The Future of Innovative Reimbursement for Cell and Gene Therapies” at World EPA Congress 2021.
Due to their complexity and cost, developers of cell and gene therapies face unique manufacturing hurdles. Determining the right approach to manufacturing is crucial when bringing these advanced therapeutics from clinical to commercialization.
This white paper, based on a recent webinar co-sponsored by Precision for Medicine and Informa Pharma Intelligence, features the unique expertise of Erin Harris (Editor In Chief of Cell & Gene), David Carr (Director, PRECISIONadvisors), Tony Khoury (Executive Vice President, Project Farma), Janet Lambert (CEO, Alliance for Regenerative Medicine), and Alex Karnal (Partner and Managing Director, Deerfield Management).
Co-hosted by Endpoints Webinars, this panel discussion will address the growing industry concerns regarding manufacturing hurdles unique to cell and gene therapy. Watch as our panel of experts helps set the landscape for the current state of the advanced therapy sector and share key considerations that go into deciding whether to scale-up manufacturing internally or look to an external supplier like a CDMO.